Researcher
Bart VAN WIJMEERSCH
- Keywords:Biomedical sciences (incl. biochemistry)
- Disciplines:Autoimmunity, Inflammation, Innate immunity, Transplantation immunology, Medical imaging and therapy not elsewhere classified, Neuroanatomy, Neurophysiology, Rehabilitation
Affiliations
- Rehabilitation Sciences (Faculty)
Member
From1 Sep 2018 → Today - Rehabilitation Research Center (Research group)
Member
From1 Sep 2018 → Today - Rehabilitation Sciences & Physiotherapy (Department)
Member
From1 Sep 2018 → Today - Biomedical Research Institute (Research institute)
Member
From1 Sep 2008 → Today - Immunology - Biochemistry (Research group)
Member
From1 Sep 2008 → 31 Aug 2018 - Physiology - Biochemistry - Immunology (Department)
Member
From1 Sep 2008 → 31 Aug 2018 - Faculty of Medicine and Life Sciences (Faculty)
Member
From1 Sep 2008 → 31 Aug 2018 - Medical Basic Sciences (Division)
Member
From1 Sep 2008 → 30 Sep 2009
Projects
1 - 9 of 9
- Empirical development of a multimodal prognostication tool to guide treatment-strategy for Multiple SclerosisFrom1 Nov 2022 → TodayFunding: BOF - doctoral mandates
- Identification of multiple sclerosis-specific cytotoxic CD4 T cellsFrom1 Mar 2022 → 1 Mar 2023Funding: Industrial enterprises
- MACSiMiSE-BRAIN: Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And NeurodegenerationFrom1 Oct 2021 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Short term changes in "Radiomic" features predict long-term treatment effectivenessFrom1 Sep 2019 → 31 Aug 2020Funding: Foreign foundations, funds with scientific view
- COGNITIVE-MOTOR INTERFERENCES DURING WALKING IN PERSONS WITH MULTIPLE SCLEROSIS: ASSESSMENT, REHABILITATION STRATEGIES AND NEURAL CORRELATESFrom1 Sep 2017 → 31 Aug 2021Funding: BOF - Doctoral projects
- Multiple sclerosis, a multidisciplinary approachFrom1 Jan 2015 → 31 Dec 2019Funding: FWO scientific research network
- T lymphocytes: from basic biology to immunotherapyFrom1 Oct 2012 → 31 Dec 2017Funding: IUAP-VII
- BOF NI project: A role for expanded CD4+CD28null T cells in patients with multiple sclerosis?From1 Jan 2012 → 31 Dec 2015Funding: BOF - Doctoral projects
- Multiple Sclerosis, a multidisciplinary appraochFrom1 Jan 2010 → 31 Dec 2014Funding: FWO scientific research network
Publications
1 - 10 of 158
- Alterations in the innate and adaptive immune system in a real-world cohort of multiple sclerosis patients treated with ocrelizumab(2024)
Authors: Lien BECKERS, Paulien BAETEN, Veronica POPESCU, Dries SWINNEN, Alessio CARDILLI, Ibrahim HAMAD, Bart VAN WIJMEERSCH, S.J. Tavernier, Markus KLEINEWIETFELD, Bieke BROUX, et al.
Pages: 109894 - Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom(2024)
Authors: T. Spelman, W. L. Herring, C. Acosta, R. Hyde, V. G. Jokubaitis, E. Pucci, A. Lugaresi, G. Laureys, E. K. Havrdova, D. Horakova, et al.
Pages: 109 - 125 - Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence(2023)
Authors: Celia Oreja-Guevara, Wallace Brownlee, Elisabeth G. Celius, Diego Centonze, Gavin Giovannoni, Suzanne Hodgkinson, Christoph Kleinschnitz, Eva Kubala Havrdova, Melinda Magyari, Daniel Selchen, et al.
- Walking to music and metronome ticks at high and low tempi in persons with progressive MS: preliminary findings(2023)
Authors: Nele VANBILSEN, Lousin MOUMDJIAN, Bart Moens, Mieke D'HOOGE, Daphne KOS, Lotte Poukens, Bart VAN WIJMEERSCH, Marc Leman, Peter FEYS
Pages: 34 - Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis(2023)
Authors: Cyrus Daruwalla, Vahid Shaygannejad, Serkan Ozakbas, Eva Kubala Havrdova, Dana Horakova, Raed Alroughani, Cavit Boz, Francesco Patti, Marco Onofrj, Alessandra Lugaresi, et al.
Pages: 875 - 883 - Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation(2023)
Authors: Chao Zhu, Tomas Kalincik, Dana Horakova, Zhen Zhou, Katherine Buzzard, Olga Skibina, Raed Alroughani, Guillermo Izquierdo, Sara Eichau, Jens Kuhle, et al.
Pages: 739 - 748 - Comparative effectiveness in multiple sclerosis: A methodological comparison(2023)
Authors: Izanne Roos, Ibrahima Diouf, Sifat SHARMIN, Dana Horakova, Eva Kubala Havrdova, Francesco Patti, Vahid Shaygannejad, Serkan Ozakbas, Guillermo Izquierdo, Sara Eichau, et al.
Pages: 326 - 332 - Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration (MACSiMiSE-BRAIN): study protocol for a multi-centre randomised placebo controlled clinical trial(2023)
Authors: Anna-Victoria De Keersmaecker, Eline VAN DONINCK, Melissa Cambron, Veronica POPESCU, Guy Laureys, Lander Willem, Miguel D' Haeseleer, Maria Bjerke, Ella Roelant, Bart VAN WIJMEERSCH, et al.
Pages: 952 - 953 - The risk of secondary progressive multiple sclerosis is geographically determined but modifiable(2023)
Authors: Sifat Sharmin, Izanne Roos, Steve Simpson-Yap, Charles Malpes, Marina M. Sanchez, Serkan Ozakbas, Dana Horakova, Eva K. Havrdova, Francesco Patti, Raed Alroughani, et al.
Pages: 4633 - 4644 - Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies(2023)
Authors: Colin M. Dayan, Beatriz Lecumberri, Ilaria Muller, Sashiananthan Ganesananthan, Samuel F. Hunter, Krzysztof W. Selmaj, Hans-Peter Hartung, Eva K. Havrdova, Christopher C. LaGanke, Tjalf Ziemssen, et al.